Head-to-head evidence
exendin-4 Fc fusion (JY09) vs PB-119
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
exendin-4 Fc fusion (JY09)
Developed by Beijing Dongfang Biotech
NCT06247748 · Phase 1 · completed
Every participant received the same open-label treatment with no control group, and the study measured drug-interaction and pharmacokinetic markers rather than a clinical benefit. No results have been posted.
PB-119
Developed by PegBio
NCT04504396 · Phase 3 · completed
This randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment. Its primary endpoint, change in HbA1c, was clearly met, with PB-119 producing a significantly larger reduction than placebo (P<0.001).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: exendin-4 Fc fusion (JY09)'s landscape · PB-119's landscape